Results 181 to 190 of about 6,708,642 (339)

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Acute Care Research Requires an Adapted Consent Procedure to Safeguard Participants' Autonomy and Rights While Limiting the Risk of Consent-Bias. [PDF]

open access: yesAcad Emerg Med
Westerhof SO   +6 more
europepmc   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

open access: yesFEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee   +3 more
wiley   +1 more source

Implementation of Digital Consent at Sandwell and West Birmingham NHS Trust: A Quality Improvement Project. [PDF]

open access: yesBMJ Open Qual
Elhariry M   +7 more
europepmc   +1 more source

Beware: Processing of Personal Data—Informed Consent Through Risk Communication [PDF]

open access: hybrid
Lukas Seiling   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy